Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Assessing asymptomatic fibrosis in alcoholic liver using Fibroscan

November’s latest issue of the Alimentary Pharmacology & Therapeutics compares Fibroscan with 7 non-invasive laboratory tests for liver fibrosis in alcoholic patients.

News image

fiogf49gjkf04

Systematic screening for liver fibrosis in heavy-drinking patients is a challenge.

Dr Nguyen-Khac and colleagues from France assessed Fibroscan for non-invasive diagnosis of asymptomatic liver fibrosis in alcohol abuse patients.

The research team determined diagnostic liver stiffness cut-off values, and compared the performance of Fibroscan with 7 non-invasive laboratory tests.

The researchers studied 103 alcoholic patients.

Liver fibrosis was staged by METAVIR system. Fibroscan, Fibrotest, Fibrometer, Hepascore, APRI, PGA, PGAA and hyaluronic acid tests were performed.

Sensitivity was 80% for F2 using Fibroscan
Alimentary Pharmacology & Therapeutics

Liver stiffness cut-offs were determined using receiver-operating characteristic curves.

Liver stiffness was correlated with fibrosis, with median at 5, 6, 8, 15 and 47 kPa for F0, F1, F2, F3, and F4 stage fibrosis, respectively.

For Fibroscan, areas under receiver-operating characteristic curves were 0.8 for F1, and 0.9 for F2 to F4.

The team noted that the diagnostic stiffness cut-offs were 6 kPa for F1, 8 kPa for F2, 11 kPa for F3, and 20 kPa for F4.

Using Fibroscan for F2, the sensitivity, specificity, positive- and negative predictive values were 80%, 91%, 93%, and 70%, respectively.

The researchers observed that using Fibroscan for F4, the sensitivity, specificity, positive- and negative predictive values were 86%, 84%, 69% and 88%, repectively.

Performance of Fibroscan was higher than 7 laboratory tests, for which areas under receiver-operating characteristic curves ranged from 0.7 to 0.8 for F1.

The area under receiver-operating characteristic curve for the performance of Fibroscan ranged from 0.5 to 0.8 for F2, 0.4 to 0.9 for F3, and 0.6 to 0.9 for F4.

Combining Fibroscan with each test, such as Hepascore, did not improve performance.

Dr Nguyen-Khac’s team concludes, “Fibroscan is effective to assess liver fibrosis in alcoholic patients.”

“Instant screening of liver fibrosis in heavy drinkers is feasible without liver biopsy.”

Aliment Pharmacol Ther 2008: 10: 1188-98


03 November 2008

Go to top of page Email this page Email this page to a colleague

 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA
 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management
 22 January 2018 
Improving symptoms in GERD
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us